Navigation Links
Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
Date:5/20/2009

arch program at the University of Cincinnati College of Medicine. "Lurasidone has the potential to be an important new therapeutic option for patients with schizophrenia."

Lurasidone's effect on weight was similar to placebo (median change 0.3 kg for overall lurasidone group vs. 0 kg for placebo) as was its effect on lipid and glucose measures. Lurasidone was also well tolerated with a lower overall discontinuation rate (31%) compared to placebo (43%) and few adverse event-related discontinuations (6% and 2% for the overall lurasidone group and placebo, respectively).

Adverse events seen in the trial were generally mild. The most commonly reported adverse events for lurasidone (greater than 5% and at least twice the rate of placebo) were akathisia (17.6% vs. 3.1% placebo), somnolence (11.7% vs. 5.5%), parkinsonism (6.8% vs. 0), and increased weight (5.1% vs. 2.4%).

"DSP is committed to the development of lurasidone and we look forward to the completion of our phase 3 clinical trial program and submission of a new drug application to the U.S. FDA," said Masayo Tada, president and chief executive officer, Dainippon Sumitomo Pharma Co., Ltd. "More importantly, we believe that lurasidone will be a valuable new treatment option for patients and physicians in addressing currently unmet needs in the treatment of schizophrenia."

"The development program for lurasidone is intended to establish efficacy for the core symptoms of schizophrenia, characterize its safety profile and explore its effects in the treatment of cognitive impairment and other areas not adequately addressed by current therapies," said Antony Loebel, M.D., vice president of clinical research, Dainippon Sumitomo Pharma America, Inc. "As a large, global trial, the PEARL 1 study is an important new addition to the existing clinical trial database."

PEARL 1 Study Design

This randomized, placebo
'/>"/>

SOURCE Dainippon Sumitomo Pharma Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... LAKE, N.J. and SAN DIEGO ... Inc. (NASDAQ: ARNA ) announced today that an ... 3 trials of lorcaserin entitled, "Early Weight Loss While on ... Weight-Loss Outcomes," was recently published in the online issue of ... Obesity Society. The objective of these analyses was to identify ...
(Date:7/30/2014)... DALLAS , July 30, 2014 /PRNewswire-iReach/ -- ... on Global and Chinese Heparin sodium (CAS 9041-08-1) ... reviews the basic information of Heparin sodium (CAS ... application and manufacturing technology. The report then explores ... (CAS 9041-08-1) & calcium (CAS 37270-89-6) listing their ...
(Date:7/30/2014)...   Epic Sciences, Inc. ("Epic"), a ... novel diagnostics to personalize and advance the treatment ... of a $30 million Series C Preferred Stock ... and Arcus Ventures, existing investors Domain Associates, Roche ... as undisclosed individual investors. With the proceeds of ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3
... NASHVILLE, Tenn., May 11, 2011 Cumberland Pharmaceuticals ... pharmaceutical company focused on hospital acute care and gastroenterology ... overview at the 2011 UBS Global Specialty Pharmaceuticals Conference ... p.m. The presentation will be simultaneously ...
... S.C., May 11, 2011 /PRNewswire-USNewswire/ -- ... announced that two client companies received big check investment ... Therapeutics and EnviroMix, both technology-based start-ups located in the ... technology and business model. Madeira Therapeutics was ...
Cached Medicine Technology:SC Launch Presents "Big Check" Investment to Two South Carolina Companies 2SC Launch Presents "Big Check" Investment to Two South Carolina Companies 3
(Date:7/31/2014)... 31, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is looking at 10 tips to ... , “Addiction recovery is a lifelong process, and one that ... committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
(Date:7/31/2014)... The study, The Truth Behind ... episode of care payments for four clinical areas—congestive heart ... replacements (hips and knees). Using the definition of ... Care Improvement program, the study examines these clinical areas ... the country. , “Our study reaffirms that, in most ...
(Date:7/30/2014)... 30, 2014 The Mesothelioma ... Penn's Abramson Cancer Center, will host a regional ... experts in the field of mesothelioma. September 26 marks ... is open to the public, and specifically aimed at ... who have been exposed to asbestos. , The conference ...
(Date:7/30/2014)... returning National Guard soldiers were more likely to ... life setbacks, including job loss, legal problems, divorce, ... military families. Results of the study by researchers ... are published online in the American Journal ... a major concern for reservists returning home. Nearly ...
(Date:7/30/2014)... (PRWEB) July 31, 2014 “United States Orthopedic ... data on the United States Orthopedic Braces and Supports market. ... volume (in units) and average price data (in US dollars), ... Supports , Ankle Braces and Supports , ... Braces and Supports. , Orthotics is a specialty ...
Breaking Medicine News(10 mins):Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 3Health News:Vets' alcohol problems linked to stress on the home front 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 3Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 4
... released figures which show that there is an incredible ... for rehabilitation treatment programs under the banner of NHS(National ... . ,Most of the centers earmarked for drug ... the in- patient wards are empty and that referral ...
... floor spasm and pain, which may now be relieved by ... symptoms of this condition are heaviness, frequency or urgency in ... Abbott of the Royal Hospital For Women, Randwick conducted a ... effect of botox on women with pelvic spasms.30 women were ...
... Carnegie Mellon University conducted a path breaking study on ... in their ability to differentiate between living and non ... The paper which can be found in the Journal ... to one of the intriguing traits of autism: the ...
... The American College of Surgeons (ACS) has accredited NewYork-Presbyterian ... with the highest possible designation (1A),// in recognition of ... available. The top-level designation is a first for New ... ,An estimated 30 percent of U.S. adults 20 years ...
... a major recent countrywide study, antipsychotic drugs that are ... in treating Alzheimer's disease as most of the patients ... ,This study was conducted by Lon Schneider, professor ... the Keck School of Medicine of the University of ...
... develop pneumococcal pneumonia -- a common bacterial pneumonia that ... October issue of Mayo Clinic Women's HealthSource is spreading ... //against this form of pneumonia and reduces the serious ... unaware of the vaccine, or may not know that ...
Cached Medicine News:Health News:NHS De-addiction, Rehabilitation waiting time ticking into months 2Health News:Autistic Children May Lag behind in ‘Categorization of Objects 2Health News:NewYork-Presbyterian Receives Highest Accreditation for Bariatric Surgery 2
Desmarres Lid Retractor thin solid blades. Size 2....
... system introduces a new level ... microsurgical instrumentation. It has an ... with advanced microcomputer control of ... operate with a full range ...
Multiple Modulation Phaco (MMP) programmability with eight surgeon settings for maximum versatility. The combination of the peristaltic power balanced pump and the piezoelectric handpiece results in ...
... is a unique combination of Paradigm's ... flexibility for modular hardware modifications and ... of changing cataract surgical techniques and ... ophthalmic surgical platforms providing open architecture ...
Medicine Products: